No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
APRE Aprea Therapeutics
- 3.140
- +0.240+8.28%
Close Dec 24 13:00 ET
- 3.100
- -0.040-1.27%
Post 17:01 ET
17.07MMarket Cap-1.12P/E (TTM)
3.166High3.060Low11.19KVolume3.090Open2.900Pre Close34.74KTurnover0.28%Turnover RatioLossP/E (Static)5.43MShares8.84752wk High0.78P/B12.50MFloat Cap2.15052wk Low--Dividend TTM3.98MShs Float1062.200Historical High--Div YieldTTM3.64%Amplitude2.150Historical Low3.105Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $20
Aprea Therapeutics' Promising ATRN-119: A Buy Rating Amid Optimized Dosing and Safety Advancements
Express News | Aprea Therapeutics Inc -Anticipates Phase 1 Readout in Second Half of 2025
Express News | Aprea Therapeutics Announces Twice Daily (Bid) Dosing of Patients in Aboya-119 Clinical Trial of Atrn-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Aprea Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Here's Why Aprea Therapeutics (APRE) Could Be Great Choice for a Bottom Fisher
Heat List
US
Overall
Symbol
Price
% Chg
No Data